Skip to content

Airflow Obstruction (AFO) in mild, moderate, and severe asthma: associations with small airway disease, clinical characteristics and Type2 biomarkers

Alex Mann
Alex Mann Senior Director, Clinical Science

Share this Article

Go straight to the Poster page to access or read the abstract below.

View Poster

Background

Airflow obstruction (AFO) and preserved ratio impaired spirometry phenotype in asthma have been associated with more exacerbations, poorer symptoms, use of ICS, and small airway dysfunction (SAD) [Cottini et al,2025]. Here we present analysis of AFO across severities of asthma in a cross-sectional asthma cohort prior to enrolment in the MAPLE-UK longitudinal study.

Authors

Alex J Mann1, Aruna T Bansal2, Melissa Bevan1, Alex Lima1, Rachna Goburdhun1, Christine Topham1, Isaacs S1, Rees K1, Mona Bafadhel3

1 hVIVO Services Ltd, London, UK; 2 Acclarogen Ltd., UK; 3 King’s Centre for Lung Health, Kings College London, UK 

View the Poster

You can view the poster here.

 

Plan your next Clinical Trial with hVIVO

If you're a potential customer, find out how hVIVO can help you.